###begin article-title 0
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
CHEK2 has previously been excluded as a major cause of Li-Fraumeni syndrome (LFS). One particular CHEK2 germline mutation, c.1100delC, has been shown to be associated with elevated breast cancer risk. The prevalence of CHEK2*1100delC differs between populations and has been found to be relatively high in the Netherlands. The question remains nevertheless whether CHEK2 germline mutations contribute to the Li-Fraumeni phenotype.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
We have screened 65 Dutch TP53-negative LFS/LFL candidate patients for CHEK2 germline mutations to determine their contribution to the LFS/LFL phenotype.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
We identified six index patients with a CHEK2 sequence variant, four with the c.1100delC variant and two sequence variants of unknown significance, p.Phe328Ser and c.1096-?_1629+?del.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
Our data show that CHEK2 is not a major LFS susceptibility gene in the Dutch population. However, CHEK2 might be a factor contributing to individual tumour development in TP53-negative cancer-prone families.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1079 1080 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1109 1114 1109 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1758 1763 1758 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 1809 1810 1809 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1657 1664 <span type="species:ncbi:9606">patient</span>
###xml 1700 1707 <span type="species:ncbi:9606">patient</span>
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant cancer syndrome predisposing for bone and soft tissue sarcoma, breast cancer, brain tumour, adrenocortical carcinoma and leukaemia [1]. The classical LFS criteria are: a proband with sarcoma aged under 45 years and a first-degree relative with any cancer aged under 45 years, plus a first or second-degree relative in the same lineage with any cancer under the age of 45 years or sarcoma at any age [2]. In addition, Li-Fraumeni-like syndrome (LFL) criteria have been formulated as a proband with any childhood tumour or a sarcoma, brain tumour or adrenocortical tumour diagnosed under 45 years of age and a first or second-degree relative in the same lineage with a typical LFS tumour at any age, plus a first or second-degree relative in the same lineage younger than 60 years with any cancer [3]. Less stringent LFL criteria were formulated by Eeles et al. as two first or second-degree relatives with typical LFS-extended tumours (classical LFS tumours plus melanoma, prostate cancer and pancreatic cancer) at any age [4]. The Chompret criteria for TP53 germline mutation testing have been updated in 2008 as: (1) a proband with a tumour belonging to the LFS tumour spectrum (sarcomas, brain tumours, pre-menopausal breast cancer, adrenocortical carcinoma, leukaemia, lung bronchoalveolar cancer) cancer before 46 years of age and at least one first or second-degree relative with an LFS tumour before 56 years of age or multiple tumours; or (2) a proband with multiple tumours two of which belong to the narrow LFS tumour spectrum and the first of which occurred before 46 years of age; or (3) a patient with adrenocortical carcinoma or a patient with breast cancer before 36 years of age without BRCA mutation, irrespective of the family history [5].
###end p 11
###begin p 12
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
In 1990 germline mutations in the TP53 gene were described in LFS [6]. So far, 419 TP53-positive families have been reported (IARC mutation database, R13, November 2008 [7]). At present, in approximately 75% of LFS and 40% of LFL families, a germline TP53 mutation can be detected [8]; i.e. 25% to 60% of LFS/LFL families do not carry a detectable germline TP53 mutation, implying the existence of alternative LFS susceptibility genes.
###end p 12
###begin p 13
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
CHEK2 is a cell cycle checkpoint kinase involved in DNA repair, cell death and cell cycle control by stabilizing the p53 protein [9]. In 1999 Bell et al. first described the possible association of the CHEK2 gene with Li-Fraumeni syndrome [10]. Subsequent studies have addressed the possible contribution of CHEK2 germline mutations to LFS and LFL syndrome, but could not confirm CHEK2 as a major gene involved in LFS [10-18].
###end p 13
###begin p 14
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 567 572 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
In other studies, the specific CHEK2 c.1100delC frameshift mutation was shown to be associated with an elevated breast cancer risk [19-22] and it has been suggested that it contributes to a hereditary breast and colorectal cancer phenotype [23]. The prevalence of this c.1100delC mutation seems to differ according to ethnic backgrounds and populations and is relatively high in the Netherlands [19,24]. We have investigated the CHEK2 gene mutation status of 65 index patients from 65 Dutch LFS/LFL families and families suggestive of LFS who had tested negative for TP53 germline mutations, to determine the contribution of CHEK2 germline mutations to the phenotype in those families.
###end p 14
###begin title 15
Methods
###end title 15
###begin p 16
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 700 706 700 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 709 715 709 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 733 734 733 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 831 837 831 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 840 846 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
All 65 affected index patients had been assessed and counselled in various clinical genetics centres because of the occurrence of different cancer types related to LFS and had as a consequence been tested for TP53 germline mutations. On the basis of the available clinical data, the TP53-negative families were classified into 3 groups: 1) classical LFS [2], 2) LFL syndrome according to Birch [3] or Eeles [4] and 3) LFS-suggestive, including childhood onset (under 18 years) sarcoma or brain tumours, two or more primary tumours at any age, two first-degree relatives with a tumour at any age, of which at least one relative has a typical LFS tumour or breast cancer under 30 years of age (without BRCA1 or BRCA2 mutations) (Table 1). In families with multiple breast cancer cases and individuals with breast and ovarian cancer, BRCA1 or BRCA2 mutations were excluded, according to standard procedures. Details are available on request.
###end p 16
###begin p 17
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
Number of TP53 negative families available for CHEK2 gene analysis divided into 3 groups: LFS, LFL, or LFS-suggestive family history (n = 65), including the cancer type in tested individuals.
###end p 17
###begin p 18
LFS = Li-Fraumeni syndrome
###end p 18
###begin p 19
LFL = Li-Fraumeni-like syndrome according to Birch or Eeles
###end p 19
###begin p 20
B = breast cancer
###end p 20
###begin p 21
S = sarcoma
###end p 21
###begin p 22
Other = other cancers, including adrenal cortical tumour, bladder cancer, brain tumour, colon cancer, kidney cancer, leukaemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer and thyroid cancer.
###end p 22
###begin p 23
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 559 560 559 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 961 967 961 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 980 986 980 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1112 1118 1112 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
DNA from peripheral blood lymphocytes was isolated according to standard procedures. Screening for TP53 germline mutations was performed by sequence analysis of all coding exons (2-11) including flanking intron-exon boundaries (details are available on request) and multiplex ligation-dependent probe amplification (MLPA) [25] (TP53 MLPA KIT, MRC Holland). In 34 TP53-negative LFS, LFL, or LFS-suggestive families all exons and flanking intron-exon boundaries of the CHEK2 gene were investigated using denaturing gradient gel electrophoresis (DGGE, see Table 1) [26]. All possible candidate variants, identified as aberrant DGGE fragments, were confirmed by sequence analysis. To avoid amplification of pseudogenes, a long range PCR was performed first for exons 10 to 14, followed by a nested PCR. Data on exons 1-10 were obtained for all patients, on exons 11-14 for 29 of the 34 individuals. All 65 TP53-negative individuals were screened for the c.1100delC CHEK2 mutation and CHEK2 DNA rearrangements by multiplex ligation-dependent probe amplification (MLPA, see Table 1). Details are available on request (CHEK2 MLPA KIT, MRC Holland). Mutation analysis was performed using the following reference sequence: CHEK2 (AF086904.1, GI:3982839, ).
###end p 23
###begin p 24
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Sequence variants were weighted according to their potential pathogenicity. Three silent sequence variants were seen and not further analysed: c.252A>G, p.Glu84Glu in exon 1, a previously reported silent polymorphism [15], found once, c.1566C>T, p.Pro522Pro and c.1608A>G, p.Pro536Pro, both in exon 14, found in five and seven families, respectively. For these three variants two splice site prediction programs were used, NetGene2 Server  and BDGP Splice Site Prediction/Neural Network ; no alternative splice sites were predicted.
###end p 24
###begin p 25
###xml 71 78 <span type="species:ncbi:9606">patient</span>
When possible, the presence of a sequence variant detected in an index patient was investigated in other affected relatives. A control group of 150 anonymous Dutch (male and female) blood donors was analysed by DGGE to determine the prevalence of the sequence variants in a general population sample.
###end p 25
###begin p 26
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
A chi-square test was used to determine the statistical significance of the proportion of CHEK2 mutation carriers in our study group compared to healthy controls.
###end p 26
###begin title 27
Results and discussion
###end title 27
###begin p 28
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 235 243 <span type="species:ncbi:9606">patients</span>
Sixty-five TP53-negative individuals from 65 families were screened for the CHEK2 1100delC germline mutation and DNA rearrangements. Thirty-four of these individuals were screened comprehensively by DGGE for CHEK2 mutations. Six index patients were found to carry a possibly pathogenic germline CHEK2 sequence variant.
###end p 28
###begin p 29
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 6 43 6 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1100delC in exon 10 of the <italic>CHEK2 </italic>gene</bold>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1329 1334 1329 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK </italic>
###xml 1454 1461 1454 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2</italic>
###xml 1504 1506 1504 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 257 264 <span type="species:ncbi:9606">patient</span>
###xml 694 701 <span type="species:ncbi:9606">patient</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
###xml 927 934 <span type="species:ncbi:9606">patient</span>
###xml 1395 1403 <span type="species:ncbi:9606">patients</span>
The c.1100delC in exon 10 of the CHEK2 gene, a mutation located in the kinase domain of the gene and abolishing the kinase activity of the protein, was detected in four index patients. In one family, a classical LFS family, the c.1100delC was detected in a patient who developed breast cancer at the age of 48 years (Figure 1A), which is in line with the c.1100delC acting as a low penetrance breast cancer susceptibility allele [19]. Relatives with a 50% chance of being a c.1100delC carrier in this family who had developed breast cancer were not available for testing. However, it is not likely to be the LFS-causing mutation in this family, considering the absence of the c.1100delC in the patient's son who developed a sarcoma at 15 years of age. In an LFL and LFS-suggestive family, the patients identified as carrying the c.1100delC had breast cancer (Figure 1B and 1D); in a fourth family, a LFS-suggestive family, the patient identified with the c.1100delC sequence variant had both breast and colorectal cancer (Figure 1C). No additional material was available for testing to see if and how the mutation segregates in these families. In all four of the c.1100delC families, this sequence variant seemed to be associated with breast cancer or breast and colorectal cancer, rather than LFS. The reported frequency of the CHEK c.1100delC in Dutch controls is 1.4%, in Dutch breast cancer patients not selected for family history 2.5% and in Dutch BRCA1/2-negative families with breast cancer 4.9%[19]. In our sample the frequency was 6.2% (4/65), significantly different from that for healthy controls (p = 0.006).
###end p 29
###begin p 30
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pedigrees of germline <italic>CHEK2 </italic>sequence variation families</bold>
###xml 472 479 <span type="species:ncbi:9606">patient</span>
Pedigrees of germline CHEK2 sequence variation families. Square symbols indicate males, round symbols indicate females, line across symbol means deceased individual. Filled symbols indicate affected individuals with diagnosis confirmed by pathology reports. A quarterly filled symbol indicate affected individuals with diagnosis by family history. Tumour type and age at diagnosis of the tumours are indicated below the individual identifiers, d = age of death. The index patient is indicated with an arrow. Abd = abdominal cancer, B = breast cancer, Bl = bladder cancer, Br = brain tumour, C = colorectal cancer, cancer = cancer of unknown origin, DFS = dermatofibrosarcoma, End = endometrial cancer, Ho = Hodgkin lymphoma, Ki = kidney cancer, L = lung cancer, Leu = leukaemia, LMS = Leiomyosarcoma, O = ovarian cancer, Oes = oesophagus carcinoma, OS = osteosarcoma, RMS = rhabdomyosarcoma, Schw = schwannoma, SG = salivary gland cancer, Sk = skin cancer, St = stomach cancer, mut + = mutation detected, mut - = mutation excluded.
###end p 30
###begin p 31
###xml 28 57 28 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">983T&gt;C, p.Phe328Ser in exon 8</bold>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 128 135 <span type="species:ncbi:9606">patient</span>
###xml 262 269 <span type="species:ncbi:9606">patient</span>
###xml 335 342 <span type="species:ncbi:9606">patient</span>
###xml 469 476 <span type="species:ncbi:9606">patient</span>
###xml 935 942 <span type="species:ncbi:9606">patient</span>
###xml 1146 1150 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1179 1188 <span type="species:ncbi:7955">zebrafish</span>
Another sequence variant, c.983T>C, p.Phe328Ser in exon 8, localised in the kinase domain of the gene, was detected in a female patient who had developed a leiomyosarcoma at 2 years of age and a schwannoma at 27 years of age (Figure 1E). The family of the index patient fulfilled the LFL criteria (Eeles [4]). The parents of the index patient are both healthy and over 60 years of age. A maternal aunt died of breast cancer at 45 years of age and a sister of the index patient's maternal grandmother died of a brain tumour; no material was available for testing. Under the assumption that these two affected family members were carriers of the mutation, penetrance would be incomplete with non-penetrance exhibited by two older healthy obligate mutation carriers. The hypothesis that the exon 8 mutation caused the complete LFL phenotype in this family is unlikely although a de novo mutation, contributing to the disease in the index patient, cannot be excluded. The p.Phe328Ser missense mutation has not been described in the literature before and was not found in 150 healthy Dutch controls. The phenylalanine in this position is conserved in mice and frogs but not in either zebrafish or C. Elegans (Ensembl, v39-Jun 2006 [27]).
###end p 31
###begin p 32
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 39 57 39 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c.1096-?_1629+?del</bold>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 172 179 <span type="species:ncbi:9606">patient</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 697 704 <span type="species:ncbi:9606">patient</span>
One CHEK2 DNA rearrangement was found, c.1096-?_1629+?del, a deletion of exons 10-14 of the gene. The family fulfilled the LFL criteria according to Birch[3] and the index patient developed breast cancer at the age of 55 years. A deletion of this size in the kinase domain of the gene will probably abolish the kinase activity. This deletion has not been described in the literature before. A deletion of exon 9-10 predicting protein truncation at codon 381 was discovered as a founder mutation among patients of Czecholovakian ancestry with breast cancer [17]. Unfortunately, no material from the daughter who developed a rhabdomyosarcoma at 22 years of age was available. Four sibs of the index patient were healthy; her father developed stomach cancer at 55 years of age.
###end p 32
###begin p 33
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 446 452 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 340 347 <span type="species:ncbi:9606">patient</span>
So far, 8 studies have been published on CHEK2 analysis of a total of 196 TP53-negative LFS families or families suggestive of LFS (Table 2) [10-17]. Of the seven variants presented, only the c.1100delC, the p.Ile157Thr and the p.Arg145Trp mutation are of reported functional significance. Bell et al [10] found the p.Ile157Thr in an index patient with three primary cancers; no other family members were tested. Allinen et al. [11] screened the CHEK2 gene in 21 LFS/LFL families and only found the p.Ile157Thr mutation; since it was found in healthy controls as well, they concluded that it does not contribute to an LFL-associated breast cancer risk. Some authors found an association between the p.Ile157Thr mutation and risk of female breast cancer [28-30], others found no association [31]. The p.Arg145Trp, leading to a destabilised protein, was described in a Li-Fraumeni-like kindred; it was only tested in one family-member with a sarcoma at 20 years and breast cancer at 42 years. It was not found in 200 controls [13].
###end p 33
###begin p 34
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
Literature on CHEK2 analysis in LFS and LFS-related families
###end p 34
###begin p 35
* = LFL and LFS-suggestive combined, subdivision not further mentioned
###end p 35
###begin p 36
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 779 785 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 581 589 <span type="species:ncbi:9606">patients</span>
In our study six index patients were found to carry a CHEK2 sequence variant by screening 65 TP53-negative index patients, with no evidence that the sequence variants found caused the complete LFS phenotype in their families. Our data are in line with the hypothesis that the CHEK2 c.1100delC might be associated with an elevated breast cancer risk [19,20], and possibly with a breast and colorectal cancer phenotype [23] or more generally a multi-organ cancer susceptibility [32]. We propose that the germline CHEK2 sequence variants contribute to tumour development in the index patients. Without these tumours, the families would not have fulfilled the established LFS/LFL criteria and TP53 germline mutation testing would not have been indicated. In this way, the individual CHEK2 sequence variants may contribute to the Li-Fraumeni phenotype seen in these families.
###end p 36
###begin p 37
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl10 </italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2 </italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP63 </italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK1 </italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAX </italic>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
Because only 75% of classical LFS families and 40% of LFL families have germline TP53 mutations, research groups have looked at candidate genes like Bcl10 [33], CDKN2 [34,35], TP63 [12], PTEN [34,36], CHEK1 [10,14] and BAX [37]; no possible alternative LFS genes were found.
###end p 37
###begin p 38
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 696 701 696 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 715 719 715 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Two polymorphisms, p.Arg72Pro (TP53 gene) and SNP309 T>G (MDM2 gene), have been shown to have a modifying effect, resulting in an earlier age of onset of cancer in TP53 mutation carriers [38,39]; there is even a synergistic effect when both polymorphisms are present. These are proposed examples of modifying factors or low penetrance gene mutations that play a role in age of onset and tumour clustering in cancer-prone families [40]. In our present study group, we investigated the possible modifier effects of these polymorphisms but found no association with an earlier age of tumour onset [41] (p.Arg72Pro, data not shown). We did find a larger proportion of homozygotes for the G-allele of MDM2 SNP309 in our TP53-negative group, suggesting a modifier effect on the TP53 negative Li-Fraumeni phenotype.
###end p 38
###begin title 39
Conclusion
###end title 39
###begin p 40
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
Our data illustrate that CHEK2 is not a major LFS susceptibility gene in the Dutch population. The CHEK2 gene might be a factor contributing to individual tumour development in families that are subsequently recognised as having a Li-Fraumeni phenotype. Although many genes have been excluded as alternative LFS genes, many more modifiers or low penetrance susceptibility genes might occur in families showing a Li-Fraumeni phenotype.
###end p 40
###begin title 41
Competing interests
###end title 41
###begin p 42
The authors declare that they have no competing interests.
###end p 42
###begin article-title 43
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
###end article-title 43
###begin article-title 44
A cancer family syndrome in twenty-four kindreds
###end article-title 44
###begin article-title 45
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
###end article-title 45
###begin article-title 46
Germline mutations in the TP53 gene
###end article-title 46
###begin article-title 47
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
###end article-title 47
###begin article-title 48
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
###end article-title 48
###begin article-title 49
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
###end article-title 49
###begin article-title 50
Germline TP53 mutations and Li-Fraumeni syndrome
###end article-title 50
###begin article-title 51
CHK2 kinase - a busy messenger
###end article-title 51
###begin article-title 52
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
###end article-title 52
###begin article-title 53
Mutation analysis of the CHK2 gene in families with hereditary breast cancer
###end article-title 53
###begin article-title 54
Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome
###end article-title 54
###begin article-title 55
Destabilization of CHK2 by a missense mutation associated with Li- Fraumeni Syndrome
###end article-title 55
###begin article-title 56
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition
###end article-title 56
###begin article-title 57
Increasing evidence that germline mutations in CHEK2 do not cause Li- Fraumeni syndrome
###end article-title 57
###begin article-title 58
The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds
###end article-title 58
###begin article-title 59
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer
###end article-title 59
###begin article-title 60
Is CHEK2 a cause of the Li-Fraumeni syndrome?
###end article-title 60
###begin article-title 61
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
###end article-title 61
###begin article-title 62
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
###end article-title 62
###begin article-title 63
###xml 97 104 <span type="species:ncbi:9606">patient</span>
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls
###end article-title 63
###begin article-title 64
Time to check CHEK2 in families with breast cancer?
###end article-title 64
###begin article-title 65
The CHEK2 1100delC Mutation Identifies Families with a Hereditary Breast and Colorectal Cancer Phenotype
###end article-title 65
###begin article-title 66
The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population
###end article-title 66
###begin article-title 67
Large Genomic Deletions and Duplications in the BRCA1 Gene Identified by a Novel Quantitative Method
###end article-title 67
###begin article-title 68
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers
###end article-title 68
###begin article-title 69
Ensembl 2005
###end article-title 69
###begin article-title 70
Association of two mutations in the CHEK2 gene with breast cancer
###end article-title 70
###begin article-title 71
CHEK2 variant I157T may be associated with increased breast cancer risk
###end article-title 71
###begin article-title 72
Breast cancer predisposing alleles in Poland
###end article-title 72
###begin article-title 73
Limited relevance of the CHEK2 gene in hereditary breast cancer
###end article-title 73
###begin article-title 74
CHEK2 is a multiorgan cancer susceptibility gene
###end article-title 74
###begin article-title 75
Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10
###end article-title 75
###begin article-title 76
Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li- Fraumeni syndrome
###end article-title 76
###begin article-title 77
Absence of germline p16(INK4a) alterations in p53 wild type Li-Fraumeni syndrome families
###end article-title 77
###begin article-title 78
Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing
###end article-title 78
###begin article-title 79
Germ line BAX alterations are infrequent in Li-Fraumeni syndrome
###end article-title 79
###begin article-title 80
###xml 133 139 <span type="species:ncbi:9606">humans</span>
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
###end article-title 80
###begin article-title 81
Impact of the MDM2 SNP309 and TP53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome
###end article-title 81
###begin article-title 82
Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome
###end article-title 82
###begin article-title 83
The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes
###end article-title 83

